Amaros AI offers the AmarosEngine, a cloud‑native platform that aggregates ophthalmic EMR notes, imaging biomarkers, genomic data, and payer claims into a unified, queryable knowledge base. Its AI/ML models generate patient‑level risk scores, treatment response predictions, and real‑time trial eligibility matches, delivering insights via configurable dashboards and export tools for clinicians, CROs, and commercial teams.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ophthalmology data is siloed across electronic health records, imaging repositories, genetic panels, and payer claims, making it difficult for clinicians and researchers to obtain a unified, real‑time view of patient status and treatment outcomes. This fragmentation hampers personalized care decisions, slows clinical trial enrollment, and limits data‑driven commercial strategy.
Solution
Amaros AI delivers the AmarosEngine™ intelligence ecosystem, a cloud‑native platform that ingests and harmonizes multimodal ophthalmic data—including EMR notes, imaging biomarkers, genomic variants, and claims information—into a single, queryable knowledge base. Advanced machine‑learning models generate patient‑level risk scores, treatment response predictions, and eligibility matches for ongoing studies, updating continuously as new data arrive. The platform integrates with major EHR systems via standard APIs, requiring no additional software installations or credential changes, so workflows remain uninterrupted. Users receive actionable insights through configurable dashboards and can export results in CSV/Excel formats or push them to document‑management tools such as Box or Dropbox. By providing near‑real‑time analytics, AmarosEngine enables clinicians to deliver precision ophthalmic care, CROs to accelerate enrollment and optimize protocol design, and commercial teams to identify adoption patterns and market opportunities.
Target Audience
Primary users are ophthalmologists and retina specialists seeking precision diagnostics, as well as CROs, pharmaceutical medical‑affairs teams, and commercial strategy groups that require integrated real‑world evidence for trial optimization and market planning.
Features
- Unified ingestion pipeline that normalizes genetics, imaging (CNV, GA, EZ loss, IRF/SRF, etc.), EMR notes, and payer claims into a relational data lake
- Proprietary AI/ML engine that produces patient‑specific risk stratification, treatment efficacy forecasts, and trial eligibility scores
- Real‑time patient matching service that auto‑generates eligibility reports for over 30 completed studies, with no manual data entry
- Seamless EHR integration via FHIR‑compatible APIs, eliminating the need for new installations or login credentials
- Export utilities for CSV/Excel and automated delivery to cloud storage platforms (Box, Dropbox, etc.) on customizable schedules
- Role‑based access control and end‑to‑end encryption to meet HIPAA and GDPR compliance requirements
- Interactive dashboards tailored for clinicians, medical affairs, and commercial analysts, supporting drill‑down into biomarker trends and utilization metrics